HRP20030190B1 - Polymorphs of an epothilone analog - Google Patents

Polymorphs of an epothilone analog

Info

Publication number
HRP20030190B1
HRP20030190B1 HR20030190A HRP20030190A HRP20030190B1 HR P20030190 B1 HRP20030190 B1 HR P20030190B1 HR 20030190 A HR20030190 A HR 20030190A HR P20030190 A HRP20030190 A HR P20030190A HR P20030190 B1 HRP20030190 B1 HR P20030190B1
Authority
HR
Croatia
Prior art keywords
unit cell
4density
cuka
filament
decomposition
Prior art date
Application number
HR20030190A
Other languages
English (en)
Croatian (hr)
Inventor
D. Dimarco John
Z. Gougoutas Jack
M. Vitez Imre
Davidovich Martha
Galella Michael
M. Malloy Timothy
Guo Zhenrong
Favreau Denis
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22845469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030190(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20030190A2 publication Critical patent/HRP20030190A2/hr
Publication of HRP20030190B1 publication Critical patent/HRP20030190B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20030190A 2000-08-16 2001-08-01 Polymorphs of an epothilone analog HRP20030190B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22559000P 2000-08-16 2000-08-16
PCT/US2001/024540 WO2002014323A2 (en) 2000-08-16 2001-08-01 Polymorphs of an epothilone analog

Publications (2)

Publication Number Publication Date
HRP20030190A2 HRP20030190A2 (en) 2003-04-30
HRP20030190B1 true HRP20030190B1 (en) 2011-07-31

Family

ID=22845469

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030190A HRP20030190B1 (en) 2000-08-16 2001-08-01 Polymorphs of an epothilone analog

Country Status (41)

Country Link
US (4) US6689802B2 (is)
EP (1) EP1309597B1 (is)
JP (1) JP5046467B2 (is)
KR (1) KR100810342B1 (is)
CN (1) CN1269821C (is)
AR (1) AR034259A1 (is)
AT (1) ATE366735T1 (is)
AU (2) AU8108201A (is)
BG (1) BG66132B1 (is)
BR (1) BR0113234A (is)
CA (1) CA2418109C (is)
CY (1) CY1107758T1 (is)
CZ (1) CZ305523B6 (is)
DE (1) DE60129334T2 (is)
DK (1) DK1309597T3 (is)
EE (1) EE05273B1 (is)
ES (1) ES2288518T3 (is)
GE (1) GEP20053495B (is)
HR (1) HRP20030190B1 (is)
HU (1) HU229314B1 (is)
IL (2) IL153993A0 (is)
IS (1) IS2845B (is)
LT (1) LT5138B (is)
LV (1) LV13032B (is)
MX (1) MXPA03001431A (is)
MY (1) MY134129A (is)
NO (1) NO328500B1 (is)
NZ (1) NZ523722A (is)
PE (1) PE20020290A1 (is)
PL (1) PL205628B1 (is)
PT (1) PT1309597E (is)
RO (1) RO123296B1 (is)
RU (1) RU2272039C2 (is)
SI (1) SI21100B (is)
SK (1) SK287876B6 (is)
TW (1) TWI320040B (is)
UA (1) UA75365C2 (is)
UY (1) UY26886A1 (is)
WO (1) WO2002014323A2 (is)
YU (1) YU12103A (is)
ZA (1) ZA200300522B (is)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
MXPA03006412A (es) * 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
EE200300323A (et) * 2001-01-25 2003-10-15 Bristol-Myers Squibb Company Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine
CN1774253A (zh) 2001-02-20 2006-05-17 布里斯托尔-迈尔斯斯奎布公司 用环氧丙酯酮衍生物治疗顽固性肿瘤
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
CA2478223C (en) * 2002-03-08 2012-05-15 Novartis Ag Combinations comprising epothilone derivatives and alkylating agents
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) * 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
AR052142A1 (es) 2004-11-18 2007-03-07 Bristol Myers Squibb Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US7693596B2 (en) 2005-12-14 2010-04-06 Dell Products L.P. System and method for configuring information handling system integrated circuits
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7919108B2 (en) * 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
JP2009532035A (ja) 2006-03-31 2009-09-10 ブリストル−マイヤーズ スクイブ カンパニー 微小管安定化剤に対する感受性を決定するためのバイオマーカーおよび方法
EP2029156A4 (en) 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
NZ574194A (en) * 2006-08-16 2011-12-22 Novartis Ag Crystal form of epothilone b and use in pharmaceutical compositions
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
WO2008103916A2 (en) * 2007-02-23 2008-08-28 The Trustees Of Columbia Univeristy In The City Of New York Compositions and methods for treating cancer or a neurotrophic disorder
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20130086534A (ko) * 2010-06-01 2013-08-02 플러스 케미칼스, 에스.에이. 익사베필론의 고체 형태
EP2793947B1 (en) 2011-12-23 2021-02-03 Innate Pharma Enzymatic conjugation of polypeptides
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
EP3564259A3 (en) 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
CN103183681B (zh) * 2013-03-06 2016-01-13 浙江海正药业股份有限公司 伊沙匹隆的新晶型及其制备方法
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
CN115398011A (zh) 2020-01-31 2022-11-25 亚拉勒提治疗欧洲私人有限公司 用于预测癌症患者的伊沙匹隆反应性的方法
CN112457320A (zh) * 2020-11-30 2021-03-09 湖北宏中药业股份有限公司 一种提高伊沙匹隆合成反应速率的方法
CN112375085A (zh) * 2020-11-30 2021-02-19 湖北宏中药业股份有限公司 一种伊沙匹隆反应液的高收率高纯度处理方法
CN112409366A (zh) * 2020-11-30 2021-02-26 湖北宏中药业股份有限公司 一种伊沙匹隆二聚体的高收率制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027890A2 (en) * 1997-12-04 1999-06-10 Bristol-Myers Squibb Company A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
WO1999042602A2 (en) * 1998-02-19 1999-08-26 Novartis Ag Fermentative preparation process for cytostatics and crystal forms thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1000809A (en) * 1960-11-02 1965-08-11 James Oakes & Company Riddings Pipe manufacture
DE2308418B2 (de) * 1972-06-21 1976-04-08 Petzetakis, Aristovoulos George, Moschaton, Piräus (Griechenland) Verfahren und vorrichtung zum herstellen eines insbesondere grosskalibrigen rohres aus thermoplastischem kunststoff
JPS5240337B2 (is) * 1973-01-29 1977-10-12
SE386365B (sv) * 1973-07-25 1976-08-09 L Brendling Behallare av plast, gummi eller annat bojligt material, spec. avsedd for uppsamling av urin och/eller fekalier
JPS6398413A (ja) * 1986-10-15 1988-04-28 Smc Corp 二重管およびその連続製造法
DE3927569A1 (de) * 1989-08-21 1991-02-28 Fritz Egger Gmbh Elektroabscheider zum abscheiden von schwebstoffen aus gasen
DE3939714A1 (de) * 1989-12-01 1991-06-06 Baedje K H Meteor Gummiwerke Schlauch
AU6431790A (en) * 1990-01-05 1991-08-05 Orscheln Co. Flexible synthetic plastic conduit
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE4206096A1 (de) * 1992-02-27 1993-09-02 Wolf Woco & Co Franz J Koaxialrohr
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
JP4183099B2 (ja) 1995-11-17 2008-11-19 ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃおよびｄ、製造法ならびに組成物
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
ES2312695T3 (es) * 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
JP2001513098A (ja) 1997-02-25 2001-08-28 ゲゼルシャフト フュア バイオテクノロギッシェ フォーシュンク エム ベー ハー（ゲー ベー エフ） 側鎖を修飾したエポチロン
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja) 1997-04-18 2008-03-26 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6384230B1 (en) 1997-07-16 2002-05-07 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
DE19747580A1 (de) 1997-10-28 1999-04-29 Siemens Ag Rangierfeld mit Anschlußleiste
TR200002299T2 (tr) 1998-02-05 2000-11-21 Novartis Ag Epotilon kompozisyonları.
DE19807505A1 (de) 1998-02-21 1999-08-26 Roland Man Druckmasch Bogenrotationsdruckmaschine mit Druckeinheiten für den Mehrfarbendruck und wenigstens einer Beschichtungseinheit
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
AU5325699A (en) * 1998-08-12 2000-03-06 Proteus Inc. Ribbed core dual wall structure
PT1140944E (pt) 1998-12-22 2004-01-30 Novartis Pharma Gmbh Derivados de epotilona e sua utilizacao como agentes antitumorais
RU2242229C2 (ru) * 1999-01-19 2004-12-20 Новартис Аг Применение эпотилонов для лечения рака
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
US6605559B1 (en) 1999-09-29 2003-08-12 Daihatsu Motor Co., Ltd. Dimethyl ether reforming catalyst
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
ES2304240T3 (es) 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
EE200300323A (et) 2001-01-25 2003-10-15 Bristol-Myers Squibb Company Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine
US9317043B2 (en) 2013-12-19 2016-04-19 Google Inc. Path based power generation control for an aerial vehicle

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027890A2 (en) * 1997-12-04 1999-06-10 Bristol-Myers Squibb Company A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
WO1999042602A2 (en) * 1998-02-19 1999-08-26 Novartis Ag Fermentative preparation process for cytostatics and crystal forms thereof

Also Published As

Publication number Publication date
MXPA03001431A (es) 2004-05-04
US6689802B2 (en) 2004-02-10
IS6714A (is) 2003-02-11
GEP20053495B (en) 2005-04-25
NO328500B1 (no) 2010-03-01
CZ2003418A3 (cs) 2004-01-14
US20020188014A1 (en) 2002-12-12
EE05273B1 (et) 2010-02-15
LV13032B (en) 2003-12-20
US20060063815A1 (en) 2006-03-23
USRE39251E1 (en) 2006-08-29
HK1052010A1 (en) 2003-08-29
HUP0300826A2 (hu) 2003-09-29
SK1342003A3 (en) 2003-09-11
NZ523722A (en) 2005-04-29
CA2418109A1 (en) 2002-02-21
TWI320040B (en) 2010-02-01
JP2004506638A (ja) 2004-03-04
DE60129334D1 (en) 2007-08-23
BG107467A (bg) 2003-09-30
ZA200300522B (en) 2004-04-20
UA75365C2 (en) 2006-04-17
AU8108201A (en) 2002-02-25
HUP0300826A3 (en) 2005-05-30
CY1107758T1 (el) 2013-06-19
IS2845B (is) 2013-08-15
ES2288518T3 (es) 2008-01-16
YU12103A (sh) 2006-08-17
RU2272039C2 (ru) 2006-03-20
HU229314B1 (en) 2013-10-28
KR20030022411A (ko) 2003-03-15
IL153993A0 (en) 2003-07-31
DK1309597T3 (da) 2007-10-22
AR034259A1 (es) 2004-02-18
BG66132B1 (bg) 2011-06-30
EE200300063A (et) 2004-12-15
EP1309597A2 (en) 2003-05-14
PT1309597E (pt) 2007-08-22
SI21100B (sl) 2009-12-31
ATE366735T1 (de) 2007-08-15
US20040157897A1 (en) 2004-08-12
JP5046467B2 (ja) 2012-10-10
NO20030707L (no) 2003-04-15
SK287876B6 (sk) 2012-02-03
SI21100A (sl) 2003-06-30
EP1309597B1 (en) 2007-07-11
BR0113234A (pt) 2004-02-25
MY134129A (en) 2007-11-30
UY26886A1 (es) 2002-03-22
LT2003017A (en) 2004-03-25
US6982276B2 (en) 2006-01-03
DE60129334T2 (de) 2008-04-03
CN1468243A (zh) 2004-01-14
US7153879B2 (en) 2006-12-26
CN1269821C (zh) 2006-08-16
NO20030707D0 (no) 2003-02-14
CZ305523B6 (cs) 2015-11-18
IL153993A (en) 2009-07-20
PL205628B1 (pl) 2010-05-31
PL365610A1 (en) 2005-01-10
CA2418109C (en) 2011-09-27
LT5138B (lt) 2004-06-25
HRP20030190A2 (en) 2003-04-30
WO2002014323A3 (en) 2002-05-02
AU2001281082B2 (en) 2007-01-04
PE20020290A1 (es) 2002-04-03
KR100810342B1 (ko) 2008-03-07
WO2002014323A2 (en) 2002-02-21
RO123296B1 (ro) 2011-06-30

Similar Documents

Publication Publication Date Title
HRP20030190B1 (en) Polymorphs of an epothilone analog
BR0112812A (pt) Titanato de potássio e magnésio lepidocrocìtico, método para fabricar o mesmo e material de fricção
RU2009131727A (ru) Макроциклические полиморфы, композиции, содержащие такие полиморфы, и способы их применения и получения
ES2135329A1 (es) Zeolita itq-3.
WO2009014158A1 (ja) リチウム二次電池用正極活物質、その製造方法及びリチウム二次電池
AU2001280438A1 (en) Substituted heterocyclic amides
WO2008132336A3 (fr) Synthèse d'un composé limpo4 et utilisation comme matériau d'électrode dans un accumulateur au lithium
EP1968139A3 (en) Positive electrode active material for non-aqueous electrolyte secondary battery and non-aqueous electrolyte secondary battery
DE69523148D1 (de) Ausscheidungsgehärtete seltene erden-nickellegierung, ihre herstellung und negative elektrode für nickel-wasserstoff-sekundärzelle
IL129805A0 (en) Amine hydrofluorides
TW200610758A (en) Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it
HU9904634D0 (en) New thiaazolidine-derivatives
AU2003241060A1 (en) New atorvastatin salts and pharmaceutical compositions containing them
WO2005026465A3 (de) Baumaterial auf basis von gips
CA2423286A1 (en) Amorphous form of cell cycle inhibitor
EP1707537A3 (en) Battery positive electrode material
DE60236072D1 (de) Wasserfreie elektrolytische lösung und lithium-sekundärbatterie
ES449068A1 (es) Procedimiento para preparar derivados de isoxazol.
PL314794A1 (en) Crystalline polymorphous form of (s,s,s)-n-(1-[2-carbocy-3-(n2-mezilolysilamino)propyl]-1-cyclopentylocabonyl)thyrosine
ES2128961A1 (es) Zeolitaitq-4.
WO2005054809A3 (en) Irciniastatins a and b
WO2004065360A3 (en) Piperazine derivatives and their use as synthesis intermediates
WO2003027060A1 (fr) Derives amide de diphenylbutane
WO2005012310A8 (ja) チエノピリジン系化合物の香料における使用、および新規チエノピリジン系化合物
SU808107A1 (ru) Способ приготовлени поглотител НА OCHOBE ОКиСи циНКА дл ОчиСТКигАзА OT СЕРНиСТыХ СОЕдиНЕНий

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20150710

Year of fee payment: 15

PBON Lapse due to non-payment of renewal fee

Effective date: 20160801